Canada’s Drug Agency | Drugs, Health Technologies and Systems.

tofacitinib

Details

Files
Generic Name:
tofacitinib
Project Status:
Pending
Therapeutic Area:
Juvenile idiopathic arthritis, idiopathic arthritis
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0757-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
​Indicated for treatment of paediatric patients (2 -18 years) with juvenile idiopathic arthritis: Extended oliogoarthritis Polyarthritis (RF+) Polyarthritis (RF-) Systemic JIA without active systemic features Psoriatric arthritis Enthesitis-related arthritis
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.

Files

Proposed Scope View PDF

Related Content

Last Updated : May 8, 2025